{"id":758126,"date":"2023-05-11T17:13:50","date_gmt":"2023-05-11T21:13:50","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-announces-upcoming-presentations-of-clinical-data-from-phase-1-2-trial-of-mb-106-a-cd20-targeted-autologous-car-t-cell-therapy\/"},"modified":"2023-05-11T17:13:50","modified_gmt":"2023-05-11T21:13:50","slug":"mustang-bio-announces-upcoming-presentations-of-clinical-data-from-phase-1-2-trial-of-mb-106-a-cd20-targeted-autologous-car-t-cell-therapy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-announces-upcoming-presentations-of-clinical-data-from-phase-1-2-trial-of-mb-106-a-cd20-targeted-autologous-car-t-cell-therapy\/","title":{"rendered":"Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1\/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy"},"content":{"rendered":"
\n

\n Data from Waldenstrom macroglobulinemia cohort selected for poster presentation at EHA2023<\/em>\n <\/p>\n

\n Outpatient treatment of follicular lymphoma selected for oral presentation at ICML<\/em>\n <\/p>\n

WORCESTER, Mass., May 11, 2023 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (\u201cMustang\u201d) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today\u2019s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Phase 1\/2 data on MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (\u201cNHL\u201d) and chronic lymphocytic leukemia (\u201cCLL\u201d), will be presented at the European Hematology Association (\u201cEHA2023\u201d) Hybrid Congress taking place June 8-11, 2023, in Frankfurt, Germany and at the International Conference on Malignant Lymphoma (\u201cICML\u201d) taking place June 13-17, 2023, in Lugano, Switzerland.<\/p>\n

Both presentations will be given by Mazyar Shadman, M.D., M.P.H., Associate Professor and physician at Fred Hutchinson Cancer Center (\u201cFred Hutch\u201d) and University of Washington. MB-106 is being developed in a collaboration between Mustang and Fred Hutch.<\/p>\n

\u201cAs we continue to progress our CD20-targeted CAR T cell therapy program, we look forward to the upcoming presentations highlighting data from the Phase 1\/2 study of MB-106 taking place at Fred Hutch. MB-106 has been demonstrating compelling clinical activity and a favorable safety profile in the ongoing Phase 1\/2 trial at Fred Hutch for patients with follicular lymphoma and Waldenstrom macroglobulinemia, a rare type of indolent B-NHL,\u201d said Manuel Litchman, M.D., President and Chief Executive Officer of Mustang. \u201cLooking ahead, Mustang plans to provide a data update in the near future from our Phase 1\/2 clinical trial evaluating the safety and efficacy of MB-106 in a multicenter setting.\u201d<\/p>\n

Details of the presentations are as follows:<\/p>\n

EHA2023 poster presentation
Title:\u00a0CD20 CAR-T Therapy with MB-106 for BTK Inhibitor-Refractory Waldenstr\u00f6m Macroglobulinemia (WM) \/ Lymphoplasmacytic Lymphoma (LPL) \u2013 Single Institution Study<\/a>
Abstract Number: P1097
Dates and Time:\u00a0Friday, June 9, 18:00 CEST (available on demand)
For more information, please visit the EHA2023 website:\u00a0https:\/\/ehaweb.org\/congress\/eha2023-hybrid-congress\/eha2023\/<\/a>.<\/p>\n

ICML oral presentation
Title: High Efficacy and Favorable Safety of 3rd Generation CD20 CAR-T (MB-106) for Outpatient Treatment of Follicular Lymphoma (FL) \u2013 Results of a Single-Institution Trial
Session 7: New CAR-T Cell Approaches
Program and Abstract Book Number: 49
Date and Time: Thursday, June 15, 15:30 to 16:45 CEST
For more information, please visit the\u00a0ICML website:\u00a0https:\/\/www.icml.ch\/icml\/home.html#<\/a>.<\/p>\n

Scientists at Fred Hutch played a role in developing these discoveries, and Fred Hutch and certain of its scientists may benefit financially from this work in the future.<\/p>\n

\n About Mustang Bio<\/strong>
\n
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating today\u2019s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR-T therapies across multiple cancers, as well as lentiviral gene therapies for severe combined immunodeficiency. Mustang\u2019s common stock is registered under the Securities Exchange Act of 1934, as amended, and Mustang files periodic reports with the U.S. Securities and Exchange Commission (\u201cSEC\u201d). Mustang was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.mustangbio.com<\/a>.<\/p>\n

\n Forward\u2010Looking Statements
<\/strong>This press release contains \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements, which are often indicated by terms such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cgoal,\u201d \u201cintend,\u201d \u201clook forward to,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould\u201d and similar expressions, include, but are not limited to, any statements relating to our growth strategy and product development programs, including the timing of and our ability to make regulatory filings such as INDs and other applications and to obtain regulatory approvals for our product candidates, statements concerning the potential of therapies and product candidates, and any other statements that are not historical facts. Forward-looking statements are based on management\u2019s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in Part I, Item 1A, \u201cRisk Factors,\u201d in our Annual Report on Form 10-K filed on March 30, 2023 and our other filings we make with the SEC. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.<\/p>\n

\n Company Contact:<\/strong>
\n
Jaclyn Jaffe
Mustang Bio, Inc.
(781) 652-4500
ir@mustangbio.com<\/a><\/p>\n

\n Investor Relations Contact:<\/strong>
\n
Daniel Ferry
LifeSci Advisors, LLC
(617) 430-7576
daniel@lifesciadvisors.com<\/a><\/p>\n

\n Media Relations Contact:<\/strong>
\n
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com<\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Data from Waldenstrom macroglobulinemia cohort selected for poster presentation at EHA2023 Outpatient treatment of follicular lymphoma selected for oral presentation at ICML WORCESTER, Mass., May 11, 2023 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (\u201cMustang\u201d) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today\u2019s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Phase 1\/2 data on MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (\u201cNHL\u201d) and chronic lymphocytic leukemia (\u201cCLL\u201d), will be presented at the European Hematology Association (\u201cEHA2023\u201d) Hybrid Congress taking place June 8-11, 2023, in Frankfurt, Germany and at the International Conference on Malignant Lymphoma … <\/p>\n

Continue reading “Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1\/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-758126","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1\/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-announces-upcoming-presentations-of-clinical-data-from-phase-1-2-trial-of-mb-106-a-cd20-targeted-autologous-car-t-cell-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1\/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Data from Waldenstrom macroglobulinemia cohort selected for poster presentation at EHA2023 Outpatient treatment of follicular lymphoma selected for oral presentation at ICML WORCESTER, Mass., May 11, 2023 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (\u201cMustang\u201d) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today\u2019s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Phase 1\/2 data on MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (\u201cNHL\u201d) and chronic lymphocytic leukemia (\u201cCLL\u201d), will be presented at the European Hematology Association (\u201cEHA2023\u201d) Hybrid Congress taking place June 8-11, 2023, in Frankfurt, Germany and at the International Conference on Malignant Lymphoma … Continue reading "Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1\/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-announces-upcoming-presentations-of-clinical-data-from-phase-1-2-trial-of-mb-106-a-cd20-targeted-autologous-car-t-cell-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-11T21:13:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNzYzMCM1NTg4NjQyIzIwNDk3NTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mustang-bio-announces-upcoming-presentations-of-clinical-data-from-phase-1-2-trial-of-mb-106-a-cd20-targeted-autologous-car-t-cell-therapy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mustang-bio-announces-upcoming-presentations-of-clinical-data-from-phase-1-2-trial-of-mb-106-a-cd20-targeted-autologous-car-t-cell-therapy\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1\\\/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy\",\"datePublished\":\"2023-05-11T21:13:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mustang-bio-announces-upcoming-presentations-of-clinical-data-from-phase-1-2-trial-of-mb-106-a-cd20-targeted-autologous-car-t-cell-therapy\\\/\"},\"wordCount\":952,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mustang-bio-announces-upcoming-presentations-of-clinical-data-from-phase-1-2-trial-of-mb-106-a-cd20-targeted-autologous-car-t-cell-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNzYzMCM1NTg4NjQyIzIwNDk3NTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mustang-bio-announces-upcoming-presentations-of-clinical-data-from-phase-1-2-trial-of-mb-106-a-cd20-targeted-autologous-car-t-cell-therapy\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mustang-bio-announces-upcoming-presentations-of-clinical-data-from-phase-1-2-trial-of-mb-106-a-cd20-targeted-autologous-car-t-cell-therapy\\\/\",\"name\":\"Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1\\\/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mustang-bio-announces-upcoming-presentations-of-clinical-data-from-phase-1-2-trial-of-mb-106-a-cd20-targeted-autologous-car-t-cell-therapy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mustang-bio-announces-upcoming-presentations-of-clinical-data-from-phase-1-2-trial-of-mb-106-a-cd20-targeted-autologous-car-t-cell-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNzYzMCM1NTg4NjQyIzIwNDk3NTc=\",\"datePublished\":\"2023-05-11T21:13:50+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mustang-bio-announces-upcoming-presentations-of-clinical-data-from-phase-1-2-trial-of-mb-106-a-cd20-targeted-autologous-car-t-cell-therapy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mustang-bio-announces-upcoming-presentations-of-clinical-data-from-phase-1-2-trial-of-mb-106-a-cd20-targeted-autologous-car-t-cell-therapy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mustang-bio-announces-upcoming-presentations-of-clinical-data-from-phase-1-2-trial-of-mb-106-a-cd20-targeted-autologous-car-t-cell-therapy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNzYzMCM1NTg4NjQyIzIwNDk3NTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNzYzMCM1NTg4NjQyIzIwNDk3NTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mustang-bio-announces-upcoming-presentations-of-clinical-data-from-phase-1-2-trial-of-mb-106-a-cd20-targeted-autologous-car-t-cell-therapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1\\\/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1\/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-announces-upcoming-presentations-of-clinical-data-from-phase-1-2-trial-of-mb-106-a-cd20-targeted-autologous-car-t-cell-therapy\/","og_locale":"en_US","og_type":"article","og_title":"Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1\/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy - Market Newsdesk","og_description":"Data from Waldenstrom macroglobulinemia cohort selected for poster presentation at EHA2023 Outpatient treatment of follicular lymphoma selected for oral presentation at ICML WORCESTER, Mass., May 11, 2023 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (\u201cMustang\u201d) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today\u2019s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Phase 1\/2 data on MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (\u201cNHL\u201d) and chronic lymphocytic leukemia (\u201cCLL\u201d), will be presented at the European Hematology Association (\u201cEHA2023\u201d) Hybrid Congress taking place June 8-11, 2023, in Frankfurt, Germany and at the International Conference on Malignant Lymphoma … Continue reading \"Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1\/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-announces-upcoming-presentations-of-clinical-data-from-phase-1-2-trial-of-mb-106-a-cd20-targeted-autologous-car-t-cell-therapy\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-11T21:13:50+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNzYzMCM1NTg4NjQyIzIwNDk3NTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-announces-upcoming-presentations-of-clinical-data-from-phase-1-2-trial-of-mb-106-a-cd20-targeted-autologous-car-t-cell-therapy\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-announces-upcoming-presentations-of-clinical-data-from-phase-1-2-trial-of-mb-106-a-cd20-targeted-autologous-car-t-cell-therapy\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1\/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy","datePublished":"2023-05-11T21:13:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-announces-upcoming-presentations-of-clinical-data-from-phase-1-2-trial-of-mb-106-a-cd20-targeted-autologous-car-t-cell-therapy\/"},"wordCount":952,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-announces-upcoming-presentations-of-clinical-data-from-phase-1-2-trial-of-mb-106-a-cd20-targeted-autologous-car-t-cell-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNzYzMCM1NTg4NjQyIzIwNDk3NTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-announces-upcoming-presentations-of-clinical-data-from-phase-1-2-trial-of-mb-106-a-cd20-targeted-autologous-car-t-cell-therapy\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-announces-upcoming-presentations-of-clinical-data-from-phase-1-2-trial-of-mb-106-a-cd20-targeted-autologous-car-t-cell-therapy\/","name":"Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1\/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-announces-upcoming-presentations-of-clinical-data-from-phase-1-2-trial-of-mb-106-a-cd20-targeted-autologous-car-t-cell-therapy\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-announces-upcoming-presentations-of-clinical-data-from-phase-1-2-trial-of-mb-106-a-cd20-targeted-autologous-car-t-cell-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNzYzMCM1NTg4NjQyIzIwNDk3NTc=","datePublished":"2023-05-11T21:13:50+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-announces-upcoming-presentations-of-clinical-data-from-phase-1-2-trial-of-mb-106-a-cd20-targeted-autologous-car-t-cell-therapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-announces-upcoming-presentations-of-clinical-data-from-phase-1-2-trial-of-mb-106-a-cd20-targeted-autologous-car-t-cell-therapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-announces-upcoming-presentations-of-clinical-data-from-phase-1-2-trial-of-mb-106-a-cd20-targeted-autologous-car-t-cell-therapy\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNzYzMCM1NTg4NjQyIzIwNDk3NTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNzYzMCM1NTg4NjQyIzIwNDk3NTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-announces-upcoming-presentations-of-clinical-data-from-phase-1-2-trial-of-mb-106-a-cd20-targeted-autologous-car-t-cell-therapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1\/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/758126","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=758126"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/758126\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=758126"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=758126"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=758126"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}